TAEK-VAC-HerBy + trastuzumab

**TAEK-VAC-HerBy + trastuzumab** is a combination immunotherapy regimen under clinical investigation for cancer. TAEK-VAC-HerBy is a first-in-class therapeutic cancer vaccine based on the non-replicating MVA-BN viral vector, encoding a membrane-bound form of human CD40L, a genetically modified HER2 (to prevent binding by trastuzumab and pertuzumab and preclude oncogenic activity), and a genetically modified form of the transcription factor Brachyury (to prevent its nuclear localization and oncogenic potential). Trastuzumab is a monoclonal antibody that targets the HER2 receptor, blocking its signal transduction and mediating antibody-dependent cell cytotoxicity. This combination is being studied for its potential to stimulate anti-tumor immunity in HER2- or Brachyury-expressing advanced cancers, especially HER2-positive breast and gastric cancers. The vaccine is designed for intravenous use, given together with trastuzumab, with or without pertuzumab, in relevant patient cohorts[1][2][3][4][5][7]. Developed and sponsored by Bavarian Nordic, the regimen is being tested primarily in adults with advanced or metastatic HER2-positive or Brachyury-expressing cancers.

Other names

TAEK-VAC-HerBy vaccine + trastuzumab